Treatment

GEN3014 DP, DARZALEX 1800 mg solution for injection clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
For: Relapsed or Refractory Multiple Myeloma (RRMM) · Diffuse Large B Cell Lymphoma (DLBCL) · Acute Myeloid Leukemia (AML)
Hungary · Spain · Czechia